potassium and magnesium asparahynat | Asparkam-L ampoules of 10 ml, 10 pieces.
Special Price
$15.52
Regular Price
$23.00
In stock
SKU
BID499737
Release form
Solution for intravenous administration
Solution for intravenous administration
Release form
Solution for intravenous administration
Packing
10 ampoules of 10 ml.
Pharmacological action
Elimination of potassium and magnesium deficiency, normalization of electrolyte balance, improved metabolism in the myocardium. The mechanism of action of the drug is associated with the effective participation of L-asparaginate in the transport of magnesium and potassium ions into the intracellular space.
Magnesium activates sodium-potassium-ATPase, Removing sodium ions from the cell and returning potassium ions reduces the sodium content and prevents its exchange for calcium in the smooth muscles of blood vessels, lowering their resistance. Potassium stimulates the synthesis of adenosine triphosphate, glycogen, proteins, acetylcholine, etc. Both ions support polarization / cell membranes. The drug regulates the conduction of impulses along nerve fibers, synaptic transmission, muscle contraction, and the work of the heart muscle. Due to magnesium ions, it participates in the processes of energy input and expenditure, normalizes membrane permeability, neuromuscular conductivity, synthesis of deoxyribonucleic and ribonucleic acids, cell growth, cell division, oxygen uptake, and phosphate synthesis.
Indications
To eliminate potassium and magnesium deficiency as an adjuvant in various manifestations of coronary heart disease, including acute myocardial infarction, chronic circulatory failure, cardiac arrhythmias (arrhythmias caused by overdose of cardiac glycosides).
Contraindications
Hypersensitivity to the drug, sorbitol, hyperkalemia, hypermagnesemia, acute and chronic renal failure, adrenal cortex insufficiency, atrioventricular block II and III degree, cardiogenic shock, oliguria, anauria, anauria, myasthenia syndrome , arterial hypotension, pregnancy, lactation, age up to 18 years (efficacy and safety have not been established).
Specific guidelines
No studies have been conducted to evaluate the effect of the drug on the ability to drive vehicles and engage in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
Composition
Active ingredients: potassium L-asparaginate anhydrous - 45.20 g (10.33 g of potassium), magnesium L-asparaginate anhydrous - 40.00 g (3, 37 g of magnesium) obtained according to the following recipe: L-aspartic acid - 74.00 g, potassium hydroxide (potassium hydroxide) - 14.82 g, magnesium oxide - 5.59 g
Excipients: sorbitol (sorbitol) - 50, 00 g, water for injection - up to 1 liter.
Dosage and administration
The drug is administered intravenously (drip or stream). The dose of the drug is determined individually depending on the indications for use. Intravenous drip is administered at a rate of 25 drops in 1 minute 1-2 times a day, 10 to 20 ml (1-2 ampoules of 10 ml or 2-4 ampoules of 5 ml), diluted in 100-200 ml of isotonic sodium chloride solution or 5% glucose solution. When injected, the contents of 1 ampoule of 10 ml or 2 ampoules of 5 ml are diluted in 20 ml of sterile water for injection or 5% glucose solution and injected slowly (not more than 5 ml per minute) into a vein.
Side effects
Nausea, dizziness, facial flushing, thirst, low blood pressure, hyporeflexia are possible. Phenomena usually disappear with a decrease in the dose of the drug.
With rapid intravenous administration, all symptoms of hyperkalemia and hypermagnesemia may appear.
Hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnesemia (hyperemia of the skin of the face, thirst, bradycardia, decreased blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions) with parenteral parenteral administration - reaction (increase in the number of extrasystoles), phlebitis.
Drug interaction
Potassium-sparing diuretics (triamteren, spironolactone), beta-blockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs - the risk of developing hyperkalemia and asolitis.
Eliminates hypokalemia caused by glucocorticosteroids.
Reduces unwanted effects of cardiac glycosides.
Due to the content of magnesium ions it reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.
Anesthetics enhance the inhibitory effect of magnesium on the central nervous system.
May enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracuria besylate, decametonium bromide, suxamethonium (chloride, bromide, iodide)).
Calcitriol increases the concentration of magnesium in blood plasma, calcium preparations - reduce the effect of magnesium.
The solution is pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerance).
Storage conditions
At a temperature of 0 to 25 РC.
Term hodnosty
2 years
Active ingredient
Potassium and magnesium asparaginate
pharmacy terms and conditions for prescription
Form of Treatment
simply entails dlya infusing
Appointment
for Adults on the appointment of doctor Appointment
Indications
Heart rhythm disturbances, Heart failure, Coronary heart disease, Potassium and magnesium deficiency, Arrhythmia, Acute heart attack myocardium, Prevention of acute myocardial infarction, myocardial infarction
Possible product names
Asparkam-L ampoules 10 ml, 10 pcs.
Russia, Russia, Russia biosynthesis
Solution for intravenous administration
Packing
10 ampoules of 10 ml.
Pharmacological action
Elimination of potassium and magnesium deficiency, normalization of electrolyte balance, improved metabolism in the myocardium. The mechanism of action of the drug is associated with the effective participation of L-asparaginate in the transport of magnesium and potassium ions into the intracellular space.
Magnesium activates sodium-potassium-ATPase, Removing sodium ions from the cell and returning potassium ions reduces the sodium content and prevents its exchange for calcium in the smooth muscles of blood vessels, lowering their resistance. Potassium stimulates the synthesis of adenosine triphosphate, glycogen, proteins, acetylcholine, etc. Both ions support polarization / cell membranes. The drug regulates the conduction of impulses along nerve fibers, synaptic transmission, muscle contraction, and the work of the heart muscle. Due to magnesium ions, it participates in the processes of energy input and expenditure, normalizes membrane permeability, neuromuscular conductivity, synthesis of deoxyribonucleic and ribonucleic acids, cell growth, cell division, oxygen uptake, and phosphate synthesis.
Indications
To eliminate potassium and magnesium deficiency as an adjuvant in various manifestations of coronary heart disease, including acute myocardial infarction, chronic circulatory failure, cardiac arrhythmias (arrhythmias caused by overdose of cardiac glycosides).
Contraindications
Hypersensitivity to the drug, sorbitol, hyperkalemia, hypermagnesemia, acute and chronic renal failure, adrenal cortex insufficiency, atrioventricular block II and III degree, cardiogenic shock, oliguria, anauria, anauria, myasthenia syndrome , arterial hypotension, pregnancy, lactation, age up to 18 years (efficacy and safety have not been established).
Specific guidelines
No studies have been conducted to evaluate the effect of the drug on the ability to drive vehicles and engage in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
Composition
Active ingredients: potassium L-asparaginate anhydrous - 45.20 g (10.33 g of potassium), magnesium L-asparaginate anhydrous - 40.00 g (3, 37 g of magnesium) obtained according to the following recipe: L-aspartic acid - 74.00 g, potassium hydroxide (potassium hydroxide) - 14.82 g, magnesium oxide - 5.59 g
Excipients: sorbitol (sorbitol) - 50, 00 g, water for injection - up to 1 liter.
Dosage and administration
The drug is administered intravenously (drip or stream). The dose of the drug is determined individually depending on the indications for use. Intravenous drip is administered at a rate of 25 drops in 1 minute 1-2 times a day, 10 to 20 ml (1-2 ampoules of 10 ml or 2-4 ampoules of 5 ml), diluted in 100-200 ml of isotonic sodium chloride solution or 5% glucose solution. When injected, the contents of 1 ampoule of 10 ml or 2 ampoules of 5 ml are diluted in 20 ml of sterile water for injection or 5% glucose solution and injected slowly (not more than 5 ml per minute) into a vein.
Side effects
Nausea, dizziness, facial flushing, thirst, low blood pressure, hyporeflexia are possible. Phenomena usually disappear with a decrease in the dose of the drug.
With rapid intravenous administration, all symptoms of hyperkalemia and hypermagnesemia may appear.
Hyperkalemia (nausea, vomiting, diarrhea, paresthesia) and hypermagnesemia (hyperemia of the skin of the face, thirst, bradycardia, decreased blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, convulsions) with parenteral parenteral administration - reaction (increase in the number of extrasystoles), phlebitis.
Drug interaction
Potassium-sparing diuretics (triamteren, spironolactone), beta-blockers, cyclosporine, heparin, angiotensin-converting enzyme inhibitors, non-steroidal anti-inflammatory drugs - the risk of developing hyperkalemia and asolitis.
Eliminates hypokalemia caused by glucocorticosteroids.
Reduces unwanted effects of cardiac glycosides.
Due to the content of magnesium ions it reduces the effect of neomycin, polymyxin B, tetracycline and streptomycin.
Anesthetics enhance the inhibitory effect of magnesium on the central nervous system.
May enhance neuromuscular blockade caused by depolarizing muscle relaxants (atracuria besylate, decametonium bromide, suxamethonium (chloride, bromide, iodide)).
Calcitriol increases the concentration of magnesium in blood plasma, calcium preparations - reduce the effect of magnesium.
The solution is pharmaceutically compatible with solutions of cardiac glycosides (improves their tolerance).
Storage conditions
At a temperature of 0 to 25 РC.
Term hodnosty
2 years
Active ingredient
Potassium and magnesium asparaginate
pharmacy terms and conditions for prescription
Form of Treatment
simply entails dlya infusing
Appointment
for Adults on the appointment of doctor Appointment
Indications
Heart rhythm disturbances, Heart failure, Coronary heart disease, Potassium and magnesium deficiency, Arrhythmia, Acute heart attack myocardium, Prevention of acute myocardial infarction, myocardial infarction
Possible product names
Asparkam-L ampoules 10 ml, 10 pcs.
Russia, Russia, Russia biosynthesis
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review